Nebispes (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebispes, is a beta‑blocker presented as an oral tablet for oral administration. It selectively blocks β1‑adrenergic receptors and enhances nitric oxide release, helping to lower elevated blood pressure and improve cardiac function in adults with hypertension or chronic heart failure.

GNH USA supplies Nebispes as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines and global logistics support.

Nebispes (nebivolol) is used in cardiovascular therapy to control blood pressure and support heart function.

- Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Heart failure with reduced ejection fraction: improves symptoms, exercise tolerance and survival. - Left ventricular dysfunction: enhances cardiac output by lowering afterload and improving ventricular relaxation.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Dizziness or light‑headedness - Fatigue or tiredness - Bradycardia (slow heart rate)

Serious or Rare Side Effects: - Severe bradycardia or heart block - Acute bronchospasm in patients with asthma or COPD - Hepatic injury or jaundice - Anaphylactic reaction or severe skin rash

Nebivolol requires careful monitoring and specific precautions to ensure safe use.

- Blood pressure monitoring: check regularly to avoid hypotension. - Cardiac function assessment: evaluate before initiating in heart failure patients. - Caution in asthma/COPD: β‑blockade may precipitate bronchospasm. - Concomitant beta‑blockers: avoid additive effects that can cause excessive bradycardia. - Renal impairment: dose may need adjustment in severe cases. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nebivolol can interact with several medicines; some combinations should be avoided while others need close monitoring.

Major Interactions (Avoid): - Other beta‑blockers: combined use can cause profound bradycardia and AV block. - Calcium channel blockers (verapamil, diltiazem): increase risk of cardiac conduction disturbances. - Clonidine abrupt withdrawal: may lead to rebound hypertension. - Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms. - MAO inhibitors: may enhance hypotensive effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy. - Diuretics: additive blood pressure lowering, monitor electrolytes. - ACE inhibitors or ARBs: potential for excessive hypotension. - Digoxin: may increase serum levels, watch for toxicity. - Antidepressants (SSRIs): monitor for bradycardia.